Generic: Imipenem/Cilastatin Sodium | Manufacturer: WG Critical Car
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A |
| 2022 | $287.0K | 757 | 284 | $3.49 |
| 2023 | $512.7K | 1,497 | 465 | $14.14 |
| State | Total Drug Cost | Claims | Prescribers | Beneficiaries |
|---|---|---|---|---|
| Florida | $758.5K | 1,511 | 257 | 339 |
| California | $367.6K | 877 | 181 | 197 |
| Texas | $305.9K | 833 | 163 | 211 |
| Ohio | $248.4K | 577 | 95 | 117 |
| North Carolina | $238.8K | 457 | 70 | 73 |
| Pennsylvania | $162.3K | 522 | 68 | 91 |
| New York | $161.3K | 334 | 94 | 102 |
| Virginia | $136.0K | 304 | 47 | 56 |
| Arizona | $101.6K | 267 | 38 | 36 |
| Georgia | $91.2K | 253 | 43 | 79 |
| South Carolina | $90.7K | 284 | 30 | 32 |
| Minnesota | $82.9K | 314 | 22 | 24 |
| Tennessee | $81.2K | 205 | 35 | 35 |
| Missouri | $79.6K | 179 | 32 | 33 |
| Michigan | $78.1K | 155 | 28 | 27 |
| Indiana | $73.5K | 178 | 28 | 47 |
| Massachusetts | $67.6K | 192 | 41 | 42 |
| Colorado | $65.4K | 101 | 14 | 15 |
| Maryland | $64.2K | 160 | 39 | 38 |
| Kentucky | $62.9K | 169 | 30 | 55 |
| New Jersey | $61.3K | 162 | 23 | 25 |
| Louisiana | $59.2K | 103 | 21 | 21 |
| Illinois | $54.2K | 145 | 38 | 34 |
| Connecticut | $52.7K | 119 | 22 | 20 |
| Hawaii | $46.8K | 102 | 8 | 14 |
| Alabama | $41.1K | 96 | 18 | 23 |
| Washington | $38.3K | 68 | 19 | 20 |
| Oklahoma | $32.3K | 77 | 9 | N/A |
| Delaware | $31.4K | 60 | 8 | 13 |
| Wisconsin | $30.9K | 48 | 7 | N/A |
| Arkansas | $30.4K | 82 | 26 | 36 |
| Rhode Island | $27.8K | 48 | 12 | 12 |
| New Hampshire | $19.4K | 38 | 5 | N/A |
| Kansas | $18.8K | 28 | 8 | N/A |
| Utah | $18.4K | 63 | 4 | N/A |
| Oregon | $17.1K | 24 | 7 | N/A |
| Mississippi | $14.4K | 40 | 6 | N/A |
| West Virginia | $8.3K | 11 | 5 | N/A |
| Nevada | $7.2K | 11 | 5 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.